Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) targeting the anti-PD-1 axis are standard first-line therapy for non-oncogene addicted non-small-cell lung cancer (NSCLC).
• While effective for some, long-term benefits of ICIs are limited to about 20% of patients, creating a challenge for subsequent treatment lines.
• Docetaxel is a current second-line option, but offers modest benefits with frequent lack of response or rapid progression.

Purpose of the Study:

• To review current second-line treatment options for NSCLC patients who have progressed on first-line ICIs.
• To discuss emerging therapeutic strategies and future perspectives in managing advanced NSCLC post-ICI failure.

Main Methods:

• Comprehensive literature review of clinical trials and published data on second-line treatments for NSCLC.
• Analysis of efficacy and safety data for various therapeutic approaches, including chemotherapy, novel combinations, and antibody-drug conjugates.
• Evaluation of preliminary and mature clinical trial results to assess treatment potential.

Main Results:

• While novel ICI combinations show preliminary activity, mature data often do not demonstrate superiority over the standard of care.
• Antibody-drug conjugates (ADCs) represent a highly promising alternative, with promising Phase I/II data expected to be confirmed by upcoming Phase III trials.
• Docetaxel provides limited benefit in the second-line setting for most patients.

Conclusions:

• The treatment landscape after first-line ICI failure in NSCLC remains challenging, necessitating exploration of novel agents.
• Antibody-drug conjugates are emerging as a leading promising strategy for second-line treatment, pending Phase III validation.
• Further research and clinical trials are crucial to optimize outcomes for patients with advanced NSCLC post-ICI therapy.